6.86
-0.17 (-2.42%)
| Penutupan Terdahulu | 7.03 |
| Buka | 7.01 |
| Jumlah Dagangan | 48,112 |
| Purata Dagangan (3B) | 267,868 |
| Modal Pasaran | 249,222,704 |
| Harga / Buku (P/B) | 2.11 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Keuntungan | -9.07% |
| Margin Operasi (TTM) | -1,668.23% |
| EPS Cair (TTM) | -0.400 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -49.20% |
| Nisbah Semasa (MRQ) | 0.120 |
| Aliran Tunai Operasi (OCF TTM) | -34.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.48 M |
| Pulangan Atas Aset (ROA TTM) | -24.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Armata Pharmaceuticals, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.50 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 69.55% |
| % Dimiliki oleh Institusi | 2.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Seacrest Wealth Management, Llc | 30 Sep 2025 | 34,954 |
| Grey Ledge Advisors, Llc | 30 Sep 2025 | 30,000 |
| Measured Wealth Private Client Group, Llc | 30 Sep 2025 | 1,000 |
| Trifecta Capital Advisors, Llc | 30 Sep 2025 | 714 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |